||Tumor necrosis factor receptor 2 (TNF Receptor 2) binds cytokines TNF-alpha and TNF-beta. At least 2 isoforms of TNF Receptor 2 are produced by alternative splicing.
This product supercedes R-1140-100.
||See product label
||A synthetic peptide corresponding to a region (103-121 aa) from human Tumor necrosis factor receptor 2. To enhance the immunological response, this peptide was coupled to carrier protein BSA.
||Tumor necrosis factor receptor 2; TNF-R2; Tumor necrosis factor receptor type II; p75; p80 TNF-alpha receptor; CD120b; Etanercept; TNFRSF1B; TNFBR; TNFR2;
||Affinity purified on antigen column
||Immunohistochemistry (IHC) and Western Blotting (WB). A concentration of 1.0 ug/mL is recommended for WB. Human TNF Receptor 2 (precursor) has a predicted length of 461 residues and MW of 48 kDa. A concentration of 1.0 ug/mL is recommended to detect the protein in formalin fixed and paraffin embedded tissues. Heat mediated antigen retrieval is required. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
||The specificity of this antibody has been confirmed by WB and IHC against the antigen.
||Lyophilised with 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3
||Reconstitute in sterile distilled water. Centrifuge to remove any insoluble material.
||At least 12 months after purchase at 2-8C (lyophilized formulations). After reconstitution, aliquot and store at -20C for a higher stability. Avoid freeze-thaw cycles.
||12 months after purchase